Diabetes Medication Safety

Diabetes medication safety is a practical discipline that most adults with diabetes are never formally taught — the focus at diagnosis and during follow-up appointments is almost always on which medications to take and how they lower blood glucose, with very little systematic attention given to the concrete behaviors that prevent medication errors, adverse events, dangerous drug interactions, and crisis situations that require emergency management. Yet the evidence consistently shows that preventable medication-related adverse events — incorrect storage causing drug degradation, unrecognized drug interactions causing hypoglycemia or glucose spikes, incorrect management of missed doses, or failure to adjust medication during illness — are among the most common causes of diabetes-related emergency department visits and hospitalizations in adults living with Type 2 diabetes. Diabetes medication safety is not a set of bureaucratic precautions — it is the practical knowledge that keeps diabetes management stable, predictable, and effective between prescriber appointments, preventing the avoidable crises that interrupt well-controlled diabetes.

Proper Storage of Diabetes Medications

Correct storage is foundational to diabetes medication safety — medications stored incorrectly may degrade silently, losing potency without any visible change, leading to unexpected blood glucose deterioration that is easy to misattribute to other causes:

• Insulin storage: Insulin is the most temperature-sensitive diabetes medication and has the most specific storage requirements. Unopened insulin vials and pens should be stored in the refrigerator (36–46°F / 2–8°C) — not in the freezer, not in the refrigerator door where temperature fluctuates most, and not next to the cooling coils. Once opened (first use), most insulin formulations can be stored at room temperature (below 77–86°F / 25–30°C depending on formulation) for 28–30 days, after which any remaining insulin should be discarded regardless of how much remains. The specific in-use stability period varies by product: insulin glargine (Lantus) 28 days, insulin detemir (Levemir) 42 days, insulin degludec (Tresiba) 56 days. Always check the product-specific prescribing information. Never use insulin that has been frozen (ice crystals permanently alter the protein structure), that appears cloudy when it should be clear (for rapid-acting and long-acting analogs), that appears clumpy or stringy, or that has changed color. Temperature-degraded insulin may look completely normal while providing dramatically reduced blood glucose control — a dangerous failure mode because it is completely invisible.
• Heat and sun exposure: Never leave insulin or any diabetes medication in a hot car, in direct sunlight, or in locations where temperature regularly exceeds 77–80°F. Car interiors in summer can reach 130–150°F within minutes — temperatures that can destroy insulin potency in a fraction of the typical in-use period. For travel, insulated cases (not ice packs directly against insulin, which can freeze it) maintain appropriate temperature. Metformin, sulfonylureas, GLP-1 receptor agonist pens, and other oral and injectable agents also have storage requirements — check each medication’s specific guidance rather than assuming room temperature storage is universally safe.
• Expiration dates: Diabetes medications should never be used past their expiration date. This applies equally to insulin, GLP-1 receptor agonist pens, oral medications, and glucagon emergency kits. Expired glucagon kits in particular represent a serious safety hazard — a household emergency that requires glucagon (severe hypoglycemia with unconsciousness) is exactly the situation where a degraded or expired glucagon kit provides false security while failing to work. Glucagon kit expiration should be checked every time medication expiration dates are reviewed and the kit replaced immediately when expired.
• GLP-1 receptor agonist pens: Weekly injectable GLP-1 medications (semaglutide/Ozempic, dulaglutide/Trulicity) require refrigerator storage before first use. Once in use, pen-specific guidance applies — most can be kept at room temperature for 4–8 weeks. The pen should be capped and stored in a cool location without the needle attached between injections. See our GLP-1 medications and diabetes guide for the full handling guidance for this class.

Drug Interactions in Diabetes Management

Drug interactions represent one of the most underappreciated dimensions of diabetes medication safety — adults with diabetes typically take multiple medications for blood pressure, cholesterol, and other comorbidities, creating an interaction landscape that requires systematic awareness:

• Interactions that increase hypoglycemia risk: Several common drug classes significantly increase hypoglycemia risk when added to insulin or sulfonylureas. Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) disrupt glucose regulation independently and have been associated with severe hypoglycemia when combined with insulin or sulfonylureas — patients on these antibiotics should increase blood glucose monitoring frequency. Azole antifungals (fluconazole — commonly prescribed for yeast infections) inhibit the liver enzymes that metabolize sulfonylureas, increasing blood sulfonylurea concentrations and extending their hypoglycemic effect for the duration of treatment and several days after. Beta-blockers (metoprolol, atenolol) — used for blood pressure and heart conditions — mask two of the most reliable hypoglycemia warning symptoms (rapid heart rate and tremor) while preserving sweating, meaning that patients on beta-blockers may experience more severe hypoglycemia before recognizing it. Alcohol inhibits hepatic glucose production, removes the liver’s ability to rescue falling blood glucose, and is associated with severe and prolonged hypoglycemia particularly when combined with insulin or sulfonylureas.
• Interactions that worsen blood glucose control: Corticosteroids (prednisone, methylprednisolone, dexamethasone) reliably raise blood glucose — often substantially — through multiple mechanisms. Adults with well-controlled diabetes who begin a course of oral steroids should expect blood glucose to rise, often requiring temporary insulin supplementation or dose adjustments of existing medications. The glucose-raising effect typically peaks 4–8 hours after the steroid dose and can persist for 12–24 hours with single daily-dose steroids. Thiazide diuretics (hydrochlorothiazide, chlorthalidone) modestly raise blood glucose and may require medication adjustment over time. Atypical antipsychotics (olanzapine, quetiapine, clozapine) cause significant metabolic changes including blood glucose elevation and weight gain — adults with diabetes starting these medications require more frequent glucose monitoring.
• Metformin and contrast media: The interaction between metformin and iodinated contrast used in CT scans and other imaging procedures deserves specific attention. Contrast media can temporarily impair kidney function; metformin accumulates when kidney function drops, increasing risk of lactic acidosis (a rare but serious complication). Current guidance recommends withholding metformin at the time of contrast administration and for 48 hours after, then resuming only after kidney function has been confirmed to be stable. Patients scheduled for any procedure involving contrast dye should notify their prescribing clinician and the radiology team that they take metformin. The complete overview of metformin safety, including this interaction and others, is in our Metformin: What Adults Should Know guide. The broader medication overview that places drug interactions in context across all drug classes is in our diabetes medications overview. The ADA medication management resources, the NIDDK diabetes medicines information, and the CDC diabetes medication resources provide authoritative guidance on drug interactions and safe medication practices for adults with diabetes.

Sick Day Rules for Diabetes Medications

Illness is one of the highest-risk periods for medication-related adverse events in diabetes. Understanding diabetes medication safety during illness — specifically which medications to continue, which to hold, and how to adjust monitoring — is essential knowledge that prevents the dangerous glucose excursions, dehydration, and medication toxicity that cause diabetes-related emergency hospitalizations:

• Why illness is dangerous in diabetes: Physical illness — viral infection, gastrointestinal illness, fever, surgical stress — triggers the release of stress hormones (cortisol, glucagon, adrenaline) that counteract insulin and raise blood glucose, often dramatically. This happens regardless of whether the person is eating normally, and even patients who are vomiting and cannot eat may have rising rather than falling blood glucose during illness. Simultaneously, illness causes dehydration through fever, sweating, vomiting, or diarrhea, which concentrates blood glucose further and impairs kidney function — creating a state where blood glucose is rising, the body is dehydrated, and many diabetes medications are less safe or less effective than usual.
• Metformin during illness — hold for significant illness: Metformin should be temporarily held during serious illness, particularly when there is vomiting, diarrhea, fever, or dehydration significant enough to reduce fluid intake. The reason is pharmacological: metformin’s rare but serious complication, lactic acidosis, occurs when the drug accumulates due to reduced kidney clearance — and kidney clearance drops with dehydration and severe illness. The clinical guideline is to hold metformin during illness that causes significant dehydration or that you would consider severe enough to seek medical attention, and resume it only when recovered and fluid intake has been normal for 24–48 hours. This is a protective precaution, not a permanent discontinuation — restarting metformin after recovery is standard practice.
• SGLT2 inhibitors during illness — hold them: SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) should be held during significant illness or any period of prolonged fasting. The reason: illness increases the risk of diabetic ketoacidosis (DKA) in all patients with diabetes, and SGLT2 inhibitors further shift metabolism toward ketone production. The combination creates risk of euglycemic DKA — dangerously elevated ketones at blood glucose levels that don’t trigger the usual clinical warning (very high blood glucose). SGLT2 inhibitors should also be held before planned surgical procedures (typically 3–4 days before). See our SGLT2 inhibitors explained guide for the full clinical detail on this risk.
• Insulin during illness — do not stop it: Unlike oral medications, insulin should never be stopped during illness even if the person is not eating or is eating very little. The stress hormone release during illness requires insulin to prevent dangerous hyperglycemia and ketoacidosis, particularly in people with Type 1 diabetes and in those with Type 2 diabetes on basal insulin. Illness protocols for insulin-dependent patients typically involve increased monitoring frequency (every 2–4 hours), adjustment of rapid-acting doses based on blood glucose results, and continuing basal insulin at or near the usual dose. Patients on insulin should discuss their specific sick day protocol with their prescribing clinician or diabetes educator — having this plan documented before illness occurs is an important component of diabetes medication safety. The complete guide to insulin management is in our insulin therapy guide.
• Sulfonylureas during illness — reduce with reduced food intake: Sulfonylureas stimulate insulin secretion regardless of blood glucose level, which means they can cause hypoglycemia during illness if food intake is reduced or delayed. Dose reduction or temporary holding of the sulfonylurea during illness with significantly reduced food intake is typically appropriate — the specific guidance depends on the agent and the severity of the illness, and should be established with the prescribing clinician as part of the patient’s sick day plan. The risks specific to sulfonylureas are covered in detail in our sulfonylureas guide.
• When to seek emergency care during illness: Adults with diabetes should seek emergency medical care during illness if: blood glucose remains above 300 mg/dL despite treatment, ketones are moderate or large on urine or blood testing, there is persistent vomiting that prevents fluid intake for more than 2–4 hours, there is confusion or altered consciousness, or the person cannot keep any fluids down for more than 4 hours. These are signs that home management has reached its limits and that clinical intervention is needed — waiting longer increases risk of DKA, severe dehydration, or hyperosmolar hyperglycemic state.

Medication Monitoring and Regular Safety Reviews

Ongoing monitoring is integral to sustained diabetes medication safety — the safe and effective dose of a diabetes medication at one point in time may not be the right dose years later as kidney function changes, weight changes, other medications are added, or the underlying diabetes progresses:

• Kidney function monitoring: Several diabetes medications require dose adjustment or discontinuation based on kidney function (measured by eGFR). Metformin should be dose-reduced at eGFR below 45 mL/min/1.73m² and discontinued below 30. Glyburide should not be used in significant kidney impairment. SGLT2 inhibitors have reduced glucose-lowering efficacy at lower eGFR levels. Insulin doses may need reduction as kidney function declines, since the kidney plays a role in insulin clearance. Kidney function should be measured at least annually in adults with Type 2 diabetes — more frequently if there is existing kidney disease or risk factors — and the results should trigger a medication review. An adult who has been on stable metformin for five years and develops CKD requires medication re-evaluation, not the same prescription continued indefinitely.
• Liver function monitoring: The liver is central to glucose metabolism and to the metabolism of several diabetes medications. Severe liver disease can reduce glucose production capacity, impairing the body’s ability to rescue itself from hypoglycemia — adults with advanced liver disease and diabetes have specific medication restrictions (metformin is contraindicated in severe hepatic impairment; many sulfonylureas require caution). Baseline liver function testing at diabetes diagnosis and periodic re-assessment is appropriate.
• Annual medication review: Every adult with diabetes benefits from a systematic annual review of their complete medication list with their prescribing clinician or pharmacist. The review should address: whether each medication is still appropriate given current kidney function, weight, blood pressure, and cardiovascular risk; whether doses need adjustment based on blood glucose control; whether new medications added for other conditions interact with existing diabetes medications; and whether any medications have been discontinued that required adjustment of diabetes medications. A medication review is particularly important after any significant health change — hospitalization, new diagnosis, or major medication change by a specialist.
• Blood glucose monitoring for medication safety: Blood glucose monitoring serves not just as a feedback tool for dietary and lifestyle decisions but as a safety monitoring system for medication. Unexpectedly low blood glucose without clear cause (didn’t skip a meal, didn’t exercise more than usual) should prompt review of medications, interactions, and any recent changes. Unexpectedly high blood glucose in previously well-controlled diabetes may indicate medication non-adherence, storage problems (particularly with insulin), a drug interaction reducing effectiveness, or a change in the underlying medical condition. Consistent, unexplained changes in glucose pattern are a signal to contact the prescribing clinician. The complete medication management context — how all diabetes drug classes work and how they interact — is in our diabetes medications overview. The practical dietary approach that supports safe medication use through consistent carbohydrate intake and meal timing is in our diabetes meal planning guide. The guidance on what to do when a medication dose is missed — for each major drug class — is in our managing missed diabetes medication doses guide. The ADA medication management guidance, the NIDDK’s diabetes medicines information, and the CDC’s diabetes medication safety resources provide the authoritative clinical foundation for safe diabetes medication practices.

Missed Doses and Adherence: The Safety Foundation

Consistent medication adherence is the single most impactful component of diabetes medication safety for most adults with diabetes — not because every missed dose causes immediate harm, but because inconsistent medication use creates unpredictable glucose patterns that undermine both safety and long-term complication prevention:

• Why adherence matters beyond blood glucose numbers: Non-adherence to diabetes medications — missing doses, taking doses at irregular times, or stopping medication without medical guidance — is the most common cause of preventable blood glucose deterioration in Type 2 diabetes. Population studies consistently show that medication adherence is the strongest single predictor of HbA1c improvement independent of the specific medications chosen, that non-adherent patients have approximately 30% higher rates of diabetes complications over 5–10 years than adherent patients with similar baseline characteristics, and that each additional medication class added increases the probability of missed doses due to complexity. Simplified regimens — once-daily medications where available, combination pills, and elimination of unnecessary medications — consistently improve adherence in clinical trials. If a medication regimen is difficult to follow because of complexity, cost, side effects, or scheduling, discussing this honestly with the prescribing clinician is a legitimate and important safety conversation, not a complaint — there are almost always alternative options or simplification strategies available.
• Barriers to adherence and practical solutions: The most common identified barriers to diabetes medication adherence are cost (particularly in populations without comprehensive pharmacy coverage), side effects (most commonly gastrointestinal side effects from metformin and GLP-1 medications), regimen complexity (multiple medications, multiple daily doses), and forgetting (particularly for once-daily medications that lack a strong behavioral anchor like a mealtime). Practical solutions that have evidence for improving adherence include: taking daily medications at the same time each day tied to a consistent daily activity (brushing teeth, morning coffee, bedtime routine); using pill organizers to visually confirm whether a dose has been taken; setting phone alarms or using medication reminder apps; discussing generic alternatives and patient assistance programs with the prescribing clinician or pharmacist when cost is a barrier; and addressing side effects directly rather than quietly stopping the medication — most side effects have management strategies or can be addressed by switching formulations or timing.
• Never stopping diabetes medication without medical guidance: Stopping a diabetes medication suddenly — without a prescriber’s direction — is one of the most common precipitating events for diabetes-related medical emergencies. Blood glucose can deteriorate rapidly within days to weeks of stopping a previously effective medication. The specific risks of abrupt medication discontinuation, why it is dangerous, and what safer alternatives exist when medication changes are needed, are covered in full in our why you should not stop diabetes medication suddenly guide. The specific guidance on what to do when a dose is missed — including drug-class-specific instructions — is in our managing missed diabetes medication doses guide.

Key Takeaways for Daily Diabetes Medication Safety

Keeping diabetes medication safety practices consistent over months and years — not just at the start of treatment — is what determines long-term outcomes. The daily habits that matter most are straightforward: store medications correctly (especially insulin), check expiration dates including your glucagon emergency kit, take medications at consistent times tied to daily anchors, understand which medications to hold during illness and why, and maintain open communication with your prescribing clinician about any changes in your health, new medications, side effects, or adherence challenges. Medications work best as part of a system that includes consistent dietary habits, regular glucose monitoring, and active patient participation in identifying and reporting changes. Our diabetes medications and low blood sugar risk guide covers the specific medications that carry hypoglycemia risk and how to recognize, treat, and prevent hypoglycemic episodes as part of day-to-day medication safety practice.

Sources: American Diabetes Association — Standards of Medical Care in Diabetes, medication safety guidance; NIDDK — diabetes medicines and treatment resources; CDC — diabetes medication management; FDA — diabetes medication safety communications and drug interaction warnings; Institute for Safe Medication Practices — diabetes medication error data; insulin storage and stability guidelines from manufacturer prescribing information (Novo Nordisk, Sanofi, Eli Lilly); pharmacological interaction data for corticosteroids, fluoroquinolones, azole antifungals, beta-blockers, and metformin-contrast interactions; American College of Radiology guidance on metformin and contrast media; ISMP medication error prevention resources for diabetes management.